| |
Sensitivity (95% CI)*
|
Specificity (95% CI)*
|
Likelihood ratio of a positive test* (95% CI)*
|
Likelihood ratio of a negative test* (95% CI)*
|
|---|
|
ALL PATIENTS
| | | | |
|
Mayo Clinic†
|
96% (54/56) (88%, 99%)
|
85% (377/445) (81%, 88%)
|
6.31 (5.04, 7.90)
|
0.02 (0.00, 0.15)
|
|
NIH
|
99% (211/214) (96%, 100%)
|
89% (575/644) (87%, 91%)
|
9.20 (7.36, 11.51)
|
0.02 (0.01, 0.05)
|
|
Vienna
|
100% (17/17) (82%, 100%)
|
100% (14/14) (78%, 100%)
|
29.17 (1.91, 445.60)
|
0.03 (0.00, 0.44)
|
|
SPORADIC PATIENTS
| | | | |
|
Mayo Clinic
|
97% (38/39) (87%, 100%)
|
84% (335/399) (80%, 87%)
|
6.07 (4.83, 7.65)
|
0.03 (0.00, 0.21)
|
|
NIH
|
99% (137/138) (99%, 100%)
|
82% (249/305) (77%, 86%)
|
5.41 (4.27, 6.85)
|
0.01 (0.00, 0.06)
|
|
Vienna
|
100% (14/14) (79%, 100%)
|
100% (14/14) (79%, 100%)
|
29.00 (1.90, 443.27)
|
0.03 (0.00, 0.53)
|
- *Calculated † 6 subjects without pheochromocytoma who had "interfering substances" noted upon measurement of the metanephrine fraction were excluded.
